The company uses small molecule-based Wnt pathway modulation to develop therapeutics for degenerative diseases, regenerative medicine, and oncology. They discover new targets and biological processes in the Wnt pathway to develop small molecule drugs that potentially address numerous degenerative conditions as well as many forms of cancer. Biosplice is developing first-in-class, small-molecule therapeutics based on pioneering science of alternative pre-mRNA splicing. Their drugs in clinical development include lorecivivint for osteoarthritis (in Phase 3), cirtuvivint for numerous cancers, and a broad pipeline that ranges from Alzheimer’s disease to other degenerative conditions.